Siponimod

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

Retrieved on: 
Friday, February 17, 2023
Launch, NASA RealWorld-InWorld Engineering Design Challenge, Neurology, DMTS, Patient, TG, Merck Serono, Therapy, RealTime, Siponimod, Sanofi, FDA, Multiple sclerosis, BTK, MS, Fine chemical, Online shopping, Pharmaceutical industry, Genentech, Novartis, Biogen, Ublituximab

EXTON, Pa., Feb. 17, 2023 /PRNewswire/ -- According to Biogen's earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third year in a row. The company attributed the 2022 decline to generic erosion, pricing pressures, and a shift in prescribing patterns.

Key Points: 
  • The company attributed the 2022 decline to generic erosion, pricing pressures, and a shift in prescribing patterns.
  • As part of its' quarterly market tracking RealTime Dynamix™ service, Spherix Global Insights probed U.S. neurologists on satisfaction with Biogen's and Novartis' MS DMTs, as well as perceptions of both companies' MS portfolios.
  • Additionally, outside of branded DMTs, the MS market could see its first-ever biosimilar, with the expected launch of Sandoz/Polpharma Biologics' biosimilar natalizumab.
  • Since 2016, Spherix Global Insights has tracked the MS market and will continue coverage of this highly dynamic space.

Global Multiple Sclerosis Drugs Market Research Report 2021 Featuring Biogen, Novartis, Roche, Bayer HealthCare, Pfizer., Merck & Co, Sanofi, Teva Pharm, GSK and Acorda Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Health, Pharmaceutical, Organization, Therapy, Cladribine, GlaxoSmithKline, Autoimmune disease, FDA, Government, Merck, Interferon, MS, SPMS, Growth, Brain, Sale, Spinal cord, Merck Serono, Multiple sclerosis, Nerve, Country, COVID-19, Distribution (marketing), Economic development, Investor, Research, Tourism, Novartis, Bayer, Disease, Siponimod, Quality of life, Immune system, Biogen, Disability, Sclerosis, Sanofi, Partnership, Pfizer, Roche, Multiple Sclerosis Society, Route of administration, RRMS, Food and Drug Administration, Fine chemical, Dietary supplement, Health insurance, Pharmaceutical industry

Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline and Acorda Therapeutics Inc.

Key Points: 
  • Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline and Acorda Therapeutics Inc.
  • The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services.
  • The multiple sclerosis drugs market covered in this report is segmented by drug class into immunomodulators, immunosuppressants, interferons, others.
  • The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market.

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

Retrieved on: 
Wednesday, October 13, 2021
Health, Nobel Prize, IM, Biotechnology, DMT, DMTS, Neurodegeneration, Ozanimod, Research, News, Vaccination, Immunoglobulin G, Congress, Nasdaq, Intellectual property, European Committee on Radiation Risk, Neuropathic pain, COVID-19, MS, Neuromuscular Disorders, Sphingosine-1-phosphate, U.S. Securities and Exchange Commission, Multiple sclerosis, RNA transfection, Natalizumab, Disease, Organic acid, Risk, Biogen, Dementia, Cleveland Clinic, BIIB, Failure, Rituximab, Neuropsychiatry, Interferon, Safety, 2021 Essex County Council election, Alemtuzumab, Ophthalmology, Drug development, IFN, Treatment, Private Securities Litigation Reform Act, Siponimod, GLOBE, MRI, Technology, S1P, Randomness, Spinal muscular atrophy, Partner, Glatiramer acetate, Movement disorders, Pharmaceutical industry, Frankincense

Using data from the MS PATHS network in the U.S., Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose.

Key Points: 
  • Using data from the MS PATHS network in the U.S., Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose.
  • Preliminary results suggest that anti-CD20 and sphingosine 1-phosphate (S1P) therapies may reduce the antibody response to COVID-19 vaccination.
  • These insights are important in helping providers and patients alike manage MS while seeking to protect patients from COVID-19 through vaccination.
  • Leveraging the unique MS PATHS network, we were able to quickly generate data on the impact of the different MS DMTs on COVID-19 vaccine antibody responses.

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 24, 2019
Health, Pharmaceutical, Multiple sclerosis, Spms, Drug pipeline, Clinical medicine, Medicine, Medical specialties, Siponimod, Multiple sclerosis research

The "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Secondary Progressive Multiple Sclerosis (SPMS) development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • clinical, pre-clinical and discovery stages for Secondary Progressive Multiple Sclerosis (SPMS)
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Secondary Progressive Multiple Sclerosis (SPMS)
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine